Chester B. Whitley

Papers

Total Citations

H-Index

About

Chester B. Whitley is a leading figure in the field of inherited metabolic diseases, with a particular focus on mucopolysaccharidoses (MPS) and related lysosomal storage disorders. His research has fundamentally advanced the understanding and clinical management of these rare, devastating conditions, especially through the development of diagnostic tools and therapeutic strategies. Among his most cited works is a 2002 paper detailing an automated semimicro method for quantifying urinary glycosaminoglycan excretion—a breakthrough that enabled convenient, globally transportable specimen analysis and became a cornerstone for MPS screening and monitoring. This work, which has garnered over 40 citations, exemplifies his commitment to translating laboratory science into accessible clinical practice. Dr. Whitley’s contributions extend to pioneering enzyme replacement therapy and gene therapy trials, significantly improving outcomes for patients with conditions like Hurler and Hunter syndromes. His impact is reflected not only in citation counts but also in his leadership roles, including directing the Lysosomal Disease Network and authoring numerous guidelines that shape international standards of care. For students and researchers, his career serves as a model of how rigorous biochemical investigation can directly transform patient lives.